drugset / Trial / NCT05075603
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.
Timeline
- Start
- 2021-08-06
- Primary completion
- 2024-12-18
- Completion
- 2025-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT-I7 | Protein / enzyme biologic | 60 ug/kg | Intramuscular |
| Subject | NT-I7 | Protein / enzyme biologic | 720 ug/kg | Intramuscular |
| Background | Axicabtagene Ciloleucel | Cell therapy | — | — |
| Background | Lisocabtagene Maraleucel | Cell therapy | — | — |
| Background | Tisagenlecleucel | Cell therapy | — | — |